Characteristics and outcomes of patients with type 2 diabetes mellitus treated with canagliflozin: A real-world analysis

BMC Endocrine Disorders

Volumn 15, Issue 1, 2015, Pages

  Buysman, Erin K ^a   Chow, Wing ^b   Henk, Henry J ^a   Rupnow, Marcia F T ^b  

^a OPTUM   (United States)

^b JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

A1C levels; Canagliflozin; Real world; Treatment patterns; Type 2 diabetes mellitus

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; CANAGLIFLOZIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HEMOGLOBIN A1C; INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA DERIVATIVE; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DIABETIC PATIENT; DRUG USE; FEMALE; FOLLOW UP; GLYCEMIC CONTROL; HEMOGLOBIN DETERMINATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PRESCRIPTION; RETROSPECTIVE STUDY; UNITED STATES; BLOOD; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; MIDDLE AGED; TREATMENT OUTCOME;

BLOOD GLUCOSE; CANAGLIFLOZIN; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; UNITED STATES;

EID: 84959238876     PISSN: None     EISSN: 14726823     Source Type: Journal    
DOI: 10.1186/s12902-015-0064-8     Document Type: Article

References (37)

1. National Diabetes Statistics Report. 2014. http://www.cdc.gov/diabetes/pubs/statsreport14/national-diabetes-report-web.pdf. Accessed 9 March 2015.
2. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38:140-9.
3. American Diabetes Association. Standards of medical care in diabetes-2015. Diabetes Care. 2015;38(Suppl1):S4.
4. UKPDS Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-53.
5. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405-12.
6. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577-89.
7. Agency for Healthcare Research and Quality. Clinical practice guideline for type 2 diabetes. 2013. http://www.guideline.gov/content.aspx?id=36628. Accessed 10 March 2015.
8. Casagrande SS, Fradkin JE, Saydah SH, Rust KF, Cowie CC. The prevalence of meeting A1C, blood pressure, and LDL goals among people with diabetes, 1988-2010. Diabetes Care. 2013;36:2271.
9. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. American Diabetes Association (ADA); European Association for the Study of Diabetes (EASD). management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35:1364-79.
10. NCQA. Proposed Changes to Existing Measure for HEDIS®1 2015: Comprehensive Diabetes Care (CDC). http://www.ncqa.org/Portals/0/HomePage/CDC.pdf. Accessed 10 March 2015.
11. Medicare Shared Savings Program. Medicare Shared Savings Program Quality Measure Benchmarks for the 2014 and 2015 Reporting Years. http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/sharedsavingsprogram/Downloads/MSSP-QM-Benchmarks.pdf. Accessed 10 March 2015.
12. Polidori D, Sha S, Mudaliar S, Ciaraldi TP, Ghosh A, Vaccaro N, et al. Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study. Diabetes Care. 2013;36:2154-61.
13. Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, et al. AACE/ACE comprehensive diabetes management algorithm 2015. Endocr Pract. 2015;21:438-47.
14. Handelsman Y, Bloomgarden ZT, Grunberger G, Umpierrez G, Zimmerman RS, Bailey TS, et al. American Association of Clinical Endocrinologists and American College of Endocrinology - clinical practice guidelines for developing a diabetes mellitus comprehensive care plan - 2015. Endocr Pract. 2015;21:1-87.
15. Annemans L, Aristides M, Kubin M. Real life data: a growing need. ISPOR Connect. 2007;13:8-12.
16. Saunders C, Byrne CD, Guthrie B, Lindsay RS, McKnight JA, Philip S, et al. External validity of randomized controlled trials of glycaemic control and vascular disease: how representative are participants? Diabet Med. 2013;30:300-8.
17. Buysman EK, Chow W, Henk HJ, Rupnow MF. Characteristics and short-term outcomes of patients with type 2 diabetes mellitus treated with canagliflozin in a real-world setting. Curr Med Res Opin. 2015;31:137-43.
18. Pharmacy Quality Alliance. Proportion of Days Covered (PDC) as a preferred method of measuring medication adherence. http://www.pqaalliance.org/images/uploads/files/PQA%20PDC%20vs%20%20MPR.pdf. Accessed May 10 2015.
19. Young BA, Lin E, Von Korff M, Simon G, Ciechanowski P, Ludman EJ, et al. Diabetes complications severity index and risk of mortalitiy, hospitalization, and healthcare utilization. Am J Manag Care. 2008;14:15-23.
20. Chang HY, Weiner JP, Richards TM, Bleich SN, Segal JB. Validating the adapted diabetes complications severity index in claims data. Am J Manag Care. 2012;18:721-6.
21. Stephens JM, Botteman MF, Hay JW. Economic impact of antidiabetic medications and glycemic control on managed care organizations: a review of the literature. J Manag Care Pharm. 2006;12:130-42.
22. Oglesby AK, Secnik K, Barron J, Al Zakwani I, Lage MJ. The association between diabetes related medical costs and glycemic control: a longitudinal analysis [abstract]. Value Health. 2005;8:356. abstract PDB16.
23. Stenlöf K, Cefalu WT, Kim KA, Alba M, Usiskin K, Tong C, et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab. 2013;15:372-82.
24. Lavalle-González FJ, Januszewicz A, Davidson J, Tong C, Qiu R, Canovatchel W, et al. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia. 2013;56:2582-92.
25. Wilding JPH, Charpentier G, Hollander P, González-Gálvez G, Mathieu C, Vercruysse F, et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial. Int J Clin Pract. 2013;67:1267-82.
26. Leiter LA, Yoon KH, Arias P, Langslet G, Xie J, Balis DA, et al. Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 study. Diabetes Care. 2015;38(3):355-64.
27. Ruokoniemi P, Sund R, Arffman M, Helin-Salmivaara A, Huupponen R, Keskimäki I, et al. Are statin trials in diabetes representative of real-world diabetes care: a population-based study on statin initiators in Finland. BMJ Open. 2014;4:e005402.
28. Pharmacy Quality Alliance. PQA Measures. http://pqaalliance.org/measures/default.asp. Accessed 10 March 2015.
29. Academy of Managed Care Pharmacy, American Pharmacists Association. Medicare star ratings: stakeholder proceedings on community pharmacy and managed care partnerships in quality. J Am Pharm Assoc. 2014;54:228-40.
30. Schectman JM, Nadkarni MM, Voss JD. The association between diabetes metabolic control and drug adherence in an indigent population. Diabetes Care. 2002;25:1015-21.
31. Schoenthaler A, Cuffee YL. A systematic review of interventions to improve adherence to diabetes medications within the patient-practitioner interaction. J Clin Outcomes Manag. 2013;20(11):494-506.
32. Jha AK, Aubert RE, Yao J, Teagarden JR, Epstein RS. Greater adherence to diabetes drugs is linked to less hospital use and could save nearly $5 billion annually. Health Aff (Millwood). 2012;31:1836-46.
33. Zullig LL, Gellad WF, Moaddeb J, Crowley MJ, Shrank W, Granger BB, et al. Improving diabetes medication adherence: successful, scalable interventions. Patient Prefer Adherence. 2015;9:139-49.
34. Pi-Sunyer FX. The impact of weight gain on motivation, compliance, and metabolic control in patients with type 2 diabetes mellitus. Postgrad Med. 2009;121:94-107.
35. Grandy S, Fox KM, Hardy E, SHIELD Study Group. Association of weight loss and medication adherence among adults with type 2 diabetes mellitus: SHIELD (Study to Help Improve Early evaluation and management of risk factors Leading to Diabetes). Curr Ther Res Clin Exp. 2013;75:77-82.
36. Traina S, Guthrie R, Slee A. The impact of weight loss on weight-related quality of life and health satisfaction: results from a trial comparing canagliflozin with sitagliptin in triple therapy among people with type 2 diabetes. Postgrad Med. 2014;126(3):7-15.
37. Nardolillo A, Kane MP, Busch RS, Watsky J, Hamilton RA. A clinical perspective of canagliflozin in the management of type 2 diabetes mellitus. Clin Med Insights Endocrinol Diabetes. 2014;7:25-30.